Replies to post #90595 on Biotech Values

[kris_kade]

India always been a double edged sword for big US pharmas. On one hand they want their patents to be protected but they continue to look into taping cheap resources even for highly skilled R&D not to speak of running clinical trials.

With no serious legal controls, US pharmas' outsourced R&D is one easy source for Indian generics companies to 'peek' thanks to resource attritions.

[DewDiligence]

Gleevec patent trial in India Supreme Court begins:

http://online.wsj.com/article/SB10000872396390444233104577594973786074692.html

See #msg-46626658 for background info.

[DewDiligence]

Gleevec-patent review by India Supreme Court delayed until 9/11/12:

http://www.reuters.com/article/2012/08/22/us-india-novartis-idUSBRE87L0AI20120822

The trial was to have started today. No reason was cited for the delay.

Please see #msg-46626658 for background info.